Analyses of PBMCs from COVID-19 patients incubated with the NLRP3 trigger nigericin revealed that the activation potential of the NLRP3 inflammasome varies across myeloid cell subsets and COVID-19 severity.50 This evidence concerns the gene NLRP3 and COVID-19.